<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02351232</url>
  </required_header>
  <id_info>
    <org_study_id>LPT2015</org_study_id>
    <secondary_id>2014-002285-76</secondary_id>
    <nct_id>NCT02351232</nct_id>
  </id_info>
  <brief_title>The Lira Pump Trial</brief_title>
  <official_title>The Lira Pump Trial. The Effects of Liraglutide in Patients With Insulin Pump Treated Type 1 Diabetes: A Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized placebo-controlled clinical trial investigating the effects of Liraglutide as an
      add-on to intensive insulin therapy in overweight insulin pump treated type 1 diabetes
      patients in suboptimal glycemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>Change in HbA1c from baseline to end of study (time 6 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>6 months</time_frame>
    <description>Change in weight from baseline to end of study (time 6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin pump settings</measure>
    <time_frame>6 months</time_frame>
    <description>Change in insulin pump settings from baseline to 3 weeks, 3 months and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose variability as measured by continuous glucose monitoring</measure>
    <time_frame>6 months</time_frame>
    <description>Change in glucose variability from baseline to 3 weeks, 3 months and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition as measured by DXA-scan</measure>
    <time_frame>6 months</time_frame>
    <description>Change in body composition from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Change in blood pressure from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile (LDL, HDL, VLDL, total cholesterol, triglycerides)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in lipid profile from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of hypoglycemia (patient reported number of episodes with blood glucose &lt;3.9 mmol/l)</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of hypoglycemia during the 6-month study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kidney function as measured by urine albumine/creatinine ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Change in kidney function from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of daily blood glucose measurements</measure>
    <time_frame>6 months</time_frame>
    <description>Number of daily blood glucose measurements during the 6-month study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diet as measured by retrospective food recording</measure>
    <time_frame>6 months</time_frame>
    <description>Change in dietary behavior from baseline to 3 and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in treatment satisfaction as measured by Diabetes Treatment Satisfaction Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Change in treatment satisfaction from baseline to 3 and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety and depression as measured by Hospital Anxiety and Depression Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Change in anxiety and depression from baseline to 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo; daily subcutaneous injection; 1.8 mg; 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes ≥ 1 year

          -  BMI &gt; 25 kg/m2

          -  Insulin pump ≥ 1 year

          -  HbA1c &gt; 58 mmol/mol

          -  Use of carbohydrate counting and the insulin pump bolus calculator

        Exclusion Criteria:

          -  Gastroparesis

          -  Impaired renal function (eGFR &lt; 60 ml/min/1.73m2)

          -  Liver disease with ALAT &gt; 2.5 times the upper limit of the reference interval

          -  Acute or chronic pancreatitis or history of chronic pancreatitis or idiopathic acute
             pancreatitis

          -  Inflammatory bowel disease

          -  History of cancer (except basal cell skin cancer) which in the investigators opinion
             could interfere with the results of the trial, or cancer during the past 5 years

          -  Thyroid adenoma

          -  Subjects with personal or family history of MTC or MEN2

          -  Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs
             affecting glucose metabolism during the study period or within 30 days prior to study
             start

          -  Known or suspected alcohol or drug abuse

          -  Other concomitant medical or psychological condition that according to the
             investigator's assessment makes the patient unsuitable for study participation

          -  Females of childbearing potential who are pregnant, breast-feeding or intend to become
             pregnant or are not using adequate contraceptive methods.

          -  Simultaneous participation in any other clinical intervention trial

          -  Known or suspected hypersensitivity to Liraglutide

          -  Inability to understand the patient information and to give informed consent

          -  Acute treatment required proliferative retinopathy or maculopathy (macular oedema)

          -  Any Cardiac disorder which in the investigators opinion could interfere with the
             safety and results of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsten Nørgaard, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Signe Schmidt</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

